Genelux Corporation
General ticker "GNLX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $133.0M (TTM average)
Genelux Corporation follows the US Stock Market performance with the rate: 14.3%.
Estimated limits based on current volatility of 2.3%: low 2.94$, high 3.08$
Factors to consider:
- Total employees count: 23 (+53.3%) as of 2023
- Top business risk factors: Insufficient funding, Labor/talent shortage/retention, Acquisition/divestiture risks, Litigation risks
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.84$, 8.52$]
- 2026-12-31 to 2027-12-31 estimated range: [2.18$, 6.78$]
Financial Metrics affecting the GNLX estimates:
- Positive: with PPE of -5.0 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 7.58 > -0.60
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: 42.59 < Shareholder equity ratio, % of 60.67 <= 64.29
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -13.66 <= 0
Short-term GNLX quotes
Long-term GNLX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.17MM | $0.01MM | $0.01MM |
| Operating Expenses | $24.34MM | $31.70MM | $33.22MM |
| Operating Income | $-24.16MM | $-31.70MM | $-33.21MM |
| Non-Operating Income | $-4.13MM | $1.83MM | $1.07MM |
| Interest Expense | $0.17MM | $0.00MM | $0.00MM |
| R&D Expense | $12.77MM | $19.00MM | $19.85MM |
| Income(Loss) | $-28.30MM | $-29.87MM | $-32.15MM |
| Net Income(Loss)* | $-28.30MM | $-29.87MM | $-32.15MM |
| Stockholders Equity | $19.47MM | $26.27MM | $11.54MM |
| Assets | $27.89MM | $34.72MM | $19.03MM |
| Operating Cash Flow | $-20.27MM | $-21.23MM | $-25.27MM |
| Capital expenditure | $1.02MM | $0.38MM | $1.10MM |
| Investing Cash Flow | $-14.72MM | $-8.13MM | $12.14MM |
| Financing Cash Flow | $44.02MM | $28.51MM | $9.89MM |
| Earnings Per Share** | $-1.16 | $-0.95 | $-0.86 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.